IP : Diurnal positive advice from EMA for Chronocort

IP Group plc - Portfolio company Diurnal announces positive scientific advice from European Medicines Agency for Chronocort^®

IP Group plc (LSE: IPO) ('IP Group' or 'the Group'), the developer of intellectual property-based businesses, notes the announcement by its portfolio company Diurnal Group plc ('Diurnal') that, following a positive meeting with the European Medicines Agency (EMA) in March 2019, it has received formal Scientific Advice from the EMA confirming the current clinical and regulatory path for Chronocort^®as a treatment for adults with congenital adrenal hyperplasia (CAH).

Consequently,Diurnal intends to submit a Marketing Authorisation Application (MAA) for Chronocort^® (modified release hydrocortisone) in Q4 2019 based upon the existing clinical data, including data to support Orphan Drug Status in the treatment of CAH. This positive outcome follows the submission of a regulatory package requesting Scientific Advice to the EMA for Chronocort^® based on detailed analysis of data from its Phase 3 study, the largest ever clinical trial programme in CAH, and the open-label safety extension study.

IP Group currently holds a direct undiluted beneficial stake of 43.3% in Diurnal, a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases.

Dr Sam Williams, IP Group Managing Partner, Life Sciences, said: 'This positive development means that the EMA has not requested a further clinical study of Chronocort, despite the recent Phase 3 not meeting its primary endpoint, and is consistent with Diurnal's intention to file its marketing application this year based on the existing data. This supports IP Group's view that the chances of approval of Chronocort in Europe are very good and, moreover, that there remains the potential for Orphan status, which would give Chronocort significant advantages over existing treatments for CAH.'

CAH is an orphan condition caused by a block in cortisol production, an essential adrenal steroid hormone required for healthy life. A lack of cortisol in turn causes the over-production of male steroid hormones (androgens). Cortisol deficiency and over-production of androgens can lead to increased mortality, infertility and severe development defects, including ambiguous genitalia, precocious puberty and short stature. Sufferers, even if treated, remain at risk of death through an adrenal crisis. The condition is estimated to affect a total of approximately 47,000 patients in Europe, with over 400,000 in the rest of the world.

For more information, please contact:

IP Group plc	www.ipgroupplc.com
Alan Aubrey, Chief Executive Officer Greg Smith, Chief Financial Officer Liz Vaughan-Adams, Communications	[phone] [phone]/[phone]
Charlotte Street Partners
Andrew Wilson	[phone]
David Gaffney	[phone]
Tom Gillingham	[phone]

Notes for editors

About IP Group

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

For more information, please visit our website atwww.ipgroupplc.com.

ENDS